

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	2
INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED BCC REPORTS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	3
CHAPTER TWO: SUMMARY.....	4
SUMMARY TABLE A GLOBAL MARKETS FOR APTAMERS, THROUGH 2014 (\$ MILLIONS) ¹	4
SUMMARY FIGURE GLOBAL MARKETS FOR APTAMERS, 2008-2014 (\$ MILLIONS) ¹	4
SUMMARY TABLE B POTENTIAL MARKETS FOR APTAMER THERAPEUTICS, THROUGH 2014 (\$ MILLIONS) ¹	5
SUMMARY TABLE C HISTORICAL U.S. SALES FOR MACUGEN, THE FIRST FDA-APPROVED APTAMER DRUG, 2005-2009 (\$ MILLIONS).....	5
SUMMARY TABLE D POTENTIAL MARKETS FOR APTAMER- BASED IN-VITRO DIAGNOSTICS, THROUGH 2014 (\$ MILLIONS) ¹	6
CHAPTER THREE: OVERVIEW	7
INTRODUCTION: APTAMERS AS AFFINITY REAGENTS	7
FIGURE 1 SIMPLIFIED SCHEMATIC OF SELEX PROCESS FOR IN- VITRO SELECTION OF (DNA) APTAMERS.....	7
APTAMERS AS SUPERIOR AFFINITY REAGENTS.....	8
TABLE 1 APTAMERS AND ANTIBODIES: KEY DIFFERENCES.....	9
INDUSTRY DEFINITION AND HISTORICAL DEVELOPMENT	10
ECONOMIC IMPORTANCE.....	10
PRODUCT LIFE CYCLE.....	11
INTELLECTUAL PROPERTY AND REGULATORY ISSUES	12
POTENTIAL FUTURE DEVELOPMENTS.....	12
Potential Future Developments (Continued)	13
CHAPTER FOUR: MARKETS BY TECHNOLOGY TYPE	14
INTRODUCTION	14
ENABLING TECHNOLOGY.....	14
OLIGONUCLEOTIDE SYNTHESIS.....	14
MODIFIED OLIGONUCLEOTIDES	15
Modified Oligonucleotides (Continued)	16
Aptamer Modifications for Diagnostic Purposes	17

	Nuclease Stability of Aptamers in the Body and ADME Properties	17
<i>TABLE 2</i>	<i>MODIFICATIONS EMPLOYED TO ENHANCE APTAMERS</i>	18
	NANOPARTICLES AND QUANTUM DOT LABELS.....	18
	NEXT-GENERATION SEQUENCING.....	19
<i>TABLE 3</i>	<i>CURRENT PRICE PER MEGABASE FOR 'NEXT GENERATION' DNA SEQUENCING (\$/MEGAPHASE)</i>	20
	SURFACE PLASMON RESONANCE	20
	BIOINFORMATICS	21
	TRENDS IN ENABLING TECHNOLOGIES	22
	APTAMERS AS DIAGNOSTIC SENSORS	22
	SELF-REPORTING SENSORS.....	22
	Self-reporting Sensors (Continued)	23
	Self-reporting Sensors (Continued)	24
	SENSOR PLATFORM TECHNOLOGIES	25
	Homogeneous Solution Assays in Microplate Readers	25
	Quartz Crystal Microbalance.....	25
	Nano- and Microcantilever Sensors Using Aptamers.....	26
	Nano- and Microcantilever ... (Continued).....	27
	Surface Plasmon Resonance (SPR) and SPR Arrays	28
	TRENDS IN APTAMERS AS DIAGNOSTICS	28
	APTAMERS AS THERAPEUTICS	29
	APTAMERS AS THERAPEUTICS (CONTINUED).....	30
	APTAMERS AND INFECTIOUS DISEASE.....	31
	APTAMER MODIFICATIONS	31
	APTAMERS AS IMAGING LABELS	31
	APPLICATION OF APTAMERS AS MODIFIERS OF SURGICAL IMPLANTS	32
	WHOLE CELL SELEX	32
	'CAPTAMERS'.....	33
	VEGF APTAMERS.....	33
<i>TABLE 4</i>	<i>MEDICALLY RELEVANT APTAMER TARGETS</i>	34
	MACUGEN'S PATH TO FDA APPROVAL	34
	CLINICAL TRIALS INVOLVING APTAMERS.....	35
	PRE-CLINICAL TRIAL STAGE.....	36
	PHASE I TRIALS.....	37
	PHASE II TRIALS	38
<i>TABLE 5</i>	<i>APTAMER CLINICAL TRIALS (C: COMPLETED, R: RECRUITING, A: ACTIVE, NOT RECRUITING, T: TERMINATED, W: WITHDRAWN, P: PENDING)</i>	39
<i>TABLE 5 (CONTINUED)</i>		40
<i>TABLE 5 (CONTINUED)</i>		41
<i>TABLE 5 (CONTINUED)</i>		42
<i>TABLE 5 (CONTINUED)</i>		43

<i>TABLE 5 (CONTINUED)</i>	44
<i>TABLE 5 (CONTINUED)</i>	45
<i>TABLE 5 (CONTINUED)</i>	46
APTAMER DELIVERY.....	46
APTAMERS AND AGE-RELATED MACULAR DEGENERATION (AMD)	47
Eyetechnology/OSI Pharmaceuticals.....	47
Ophthotech.....	47
Ophthotech (Continued)	48
APTAMERS IN CANCER.....	49
Antisoma/Archemix	49
Aptamers to Biomarkers — Tenascin-C	49
Enzon Pharmaceuticals, Inc.....	50
Archemix/Merck KGaA	50
Aptamer-Drug Conjugates	51
Aptagen.....	51
APTAMERS AS ANTICOAGULANTS.....	52
APTAMERS IN OTHER INDICATIONS.....	53
TRENDS IN APTAMERS AS THERAPEUTICS.....	54
<i>TABLE 6 EMERGING APPLICATIONS FOR APTAMERS IN THERAPEUTICS</i>	54
<i>TABLE 6 (CONTINUED)</i>	55
APTAMERS IN BIOSEPARATION	55
APTAMERS AS RESEARCH TOOLS	56
<i>TABLE 7 NUMBER OF NIH FUNDED GRANTS EMPLOYING APTAMERS, 2005-2009</i>	57
<i>TABLE 8 NIH FUNDING FOR DISEASES CONSIDERED AS POSSIBLE APPLICATIONS FOR APTAMERS, 2005-2010 (\$ MILLIONS)</i>	57
<i>TABLE 9 NIH FUNDING FOR TECHNOLOGIES CONSIDERED AS POSSIBLE APPLICATIONS FOR APTAMERS, 2005-2010 (\$ MILLIONS)</i>	58
<i>TABLE 10 TOTAL NIH FUNDING (\$ MILLIONS)</i>	58
<i>TABLE 11 NUMBER OF PUBLICATIONS IN ISI WEB OF KNOWLEDGE UNDER THE TOPIC “APTAMER”</i>	58
MARKET LEADERS (U.S.).....	59
ARCHEMIX	59
Collaborations.....	59
OSI PHARMACEUTICALS	60
REGADO.....	60
OPHTHOTECH.....	61
MARKET LEADERS (INTERNATIONAL)	62
NOXXON	62
Noxxon (Continued).....	63

NASCACELL.....	64
CHAPTER FIVE: MARKETS BY APPLICATIONS	65
INTRODUCTION	65
APPLICATION OF APTAMERS AS DIAGNOSTICS.....	65
APPLICATION OF APTAMERS IN HUMAN CLINICAL	
DIAGNOSTIC ASSAYS.....	65
Application of Aptamers ... (Continued).....	66
APPLICATION OF APTAMERS IN ENVIRONMENTAL	
MONITORING AND FOOD AND WATER SAFETY	67
Application Example #1 — Veterinary Residue Testing	67
TABLE 12 EXAMPLE OF VETERINARY RESIDUE TESTS (ELISAS)	
OFFERED BY A LEADING U.S. VENDOR (ABRAXIS KITS, LLC).....	68
TABLE 12 (CONTINUED).....	69
TABLE 12 (CONTINUED).....	70
TABLE 12 (CONTINUED).....	71
TABLE 13 OTHER ENVIRONMENTAL ELISAS OFFERED BY	
ABRAXIS KITS, LLC ¹	71
TABLE 13 (CONTINUED).....	72
Application Example #2 — Algal Toxin Sensing.....	72
APPLICATION OF APTAMERS IN VETERINARY	
DIAGNOSTICS.....	73
TABLE 14 NUMBERS OF RESEARCH GRANTS FROM THE USDA	
ON ZOOBOTIC DISEASES.....	74
TABLE 14 (CONTINUED).....	75
TABLE 15 USDA-SPONSORED RESEARCH GRANTS ON	
“APTAMERS”.....	75
TABLE 15 (CONTINUED).....	76
Application Example #3 — Foot and Mouth Disease	
(FMD) Virus.....	76
Application Example #3 ... (Continued)	77
Application Example #3 ... (Continued)	78
Application Example #4 — <i>Leptospira</i> Detection	79
OVERALL MARKET POTENTIAL OF APTAMERS IN	
DIAGNOSTICS AND ENVIRONMENTAL TESTING	80
TABLE 16 U.S. DIAGNOSTICS AND TESTING MARKETS IN WHICH	
APTAMERS COULD PLAY A SIGNIFICANT ROLE (\$ MILLIONS) ¹	81
MARKET SECTOR.....	81
APPLICATION OF APTAMERS AS THERAPEUTICS	81
APTAMER DRUGS CURRENTLY ON THE MARKET.....	81
Pegaptanib	81
TABLE 17 MARKET COMPARISON (MACUGEN, LUCENTIS, AND	
AVASTIN).....	82
PROJECTED TO REACH THE MARKET WITHIN 5 YEARS	82
ARC1779	82

AS1411	82
E10030	83
Nox-A-12	83
Nox-E-36	83
NU-172	84
REG1	84
CONDITIONS TARGETED BY APTAMERS	84
Chronic Inflammatory Disease	84
Stem Cell Technology	85
Acute Coronary Syndrome	85
AMD	85
APPLICATION OF APTAMERS AS DRUG DELIVERY	
VEHICLES IN CANCER	86
TABLE 18 GLOBAL THERAPEUTICS MARKETS ADDRESSABLE IN	
NEAR TERM BY APTAMERS, THROUGH 2014 (\$ MILLIONS).....	87
TABLE 19 CANCER THERAPEUTICS MARKETS IN THE U.S. BY	
SUBINDICATION (\$ BILLIONS).....	88
APPLICATION OF APTAMERS AS MODIFIERS OF	
SURGICAL IMPLANTS	88
APPLICATION OF APTAMERS IN BIOSEPARATION	
PROCESSES	88
Application of Aptamers (Continued)	89
CHAPTER SIX: INTELLECTUAL PROPERTY ANALYSIS	90
BRIEF HISTORY	90
APTAMERS AND SELEX AS PATENTABLE SUBJECT MATTER.....	90
ORIGINAL APTAMER AND SELEX PATENTS	91
VALIDITY, LEGAL ACTION, AND INFRINGEMENT	92
VALIDITY, LEGAL ACTION, AND ... (CONTINUED).....	93
TABLE 20 MAJOR HOLDERS OF APTAMER/SELEX IP	94
TABLE 21 STRATEGIC (KNOWN OR PUBLISHED) TECHNOLOGY	
AND R&D ALLIANCES	94
TABLE 21 (CONTINUED).....	95
TABLE 21 (CONTINUED).....	96
TABLE 22 SELECTED APTAMER PATENTS	97
TABLE 22 (CONTINUED).....	98
TABLE 22 (CONTINUED).....	99
TABLE 22 (CONTINUED).....	100
TABLE 22 (CONTINUED).....	101
TABLE 22 (CONTINUED).....	102
TABLE 22 (CONTINUED).....	103
TABLE 22 (CONTINUED).....	104
TABLE 22 (CONTINUED).....	105
TABLE 23 SELECTED U.S. PATENT APPLICATIONS FOR	
THERAPEUTIC APTAMERS	105

CHAPTER SEVEN: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS	106
APTAMER TECHNOLOGY IN THE BIOSCIENCE INDUSTRY	106
<i>FIGURE 2. COMPARISON OF TRADITIONAL SMALL MOLECULE, PROTEIN, AND APTAMER-BASED MODALITIES</i>	107
THE EVOLVING APTAMER IP LANDSCAPE	107
THE EVOLVING APTAMER ... (CONTINUED)	108
APTAMERS AND THE BIOTECHNOLOGY ECOSYSTEM.....	109
THERAPEUTICS	109
DIAGNOSTICS	109
OTHER APPLICATIONS	110
SIGNIFICANT OBSTACLES TO THE APTAMER INDUSTRY	111
CURRENT APTAMER MARKET LEADERS.....	112
<i>FIGURE 3 APTAMER INDUSTRY STRUCTURE</i>	112
Current Aptamer Market Leaders (Continued)	113
Current Aptamer Market Leaders (Continued	114
PORTER MODEL ANALYSIS OF THE APTAMER INDUSTRY	115
THREAT OF SUBSTITUTE PRODUCTS IS HIGH	115
THREAT OF NEW ENTRANTS IS LOW (BUT LIKELY TO INCREASE).....	115
BARGAINING POWER OF SUPPLIERS IS LOW.....	115
BARGAINING POWER OF CUSTOMERS IS HIGH.....	116
INTRA-INDUSTRY COMPETITION IS LOW	116
<i>FIGURE 4 PORTER ANALYSIS OF THE APTAMER INDUSTRY</i>	116
CHAPTER EIGHT: COMPANY PROFILES	117
ABRAXIS KITS, LLC.....	117
ALIMERA SCIENCES.....	117
ALNYLAM PHARMACEUTICALS	117
AM BIOTECHNOLOGIES, LLC	117
APTAGEN, LLC.....	118
ARCHEMIX CORP.	119
COLLABORATIONS.....	120
AVANIR PHARMACEUTICALS.....	120
ANGIOGENIX.....	120
ANESIVA, INC.....	121
CYTOGENIX, INC.	121
ENVIROLOGIX, INC.....	122
ENZON PHARMACEUTICALS INC.	122
EYETECH	122
ISIS PHARMACEUTICALS.....	122
NOXXON.....	123
NOXXON (CONTINUED).....	124
OPHTHOTECH CORPORATION.....	125
OSI PHARMACEUTICALS, INC.....	126

REGADO BIOSCIENCES	126
QUEST DIAGNOSTICS CORPORATE HEADQUARTERS.....	127
MITSUI & CO. (U.S.A.), INC.	127
SOMALOGIC, INC.	127
SUMITOMO BAKELITE-NORTH AMERICA, INC.	127
CHAPTER NINE: REFERENCES.....	128
REFERENCES.....	128
REFERENCES (CONTINUED)	129
REFERENCES (CONTINUED)	130
REFERENCES (CONTINUED)	131
REFERENCES (CONTINUED)	132
REFERENCES (CONTINUED)	133
REFERENCES (CONTINUED)	134
REFERENCES (CONTINUED)	135
REFERENCES (CONTINUED)	136
REFERENCES (CONTINUED)	137
REFERENCES (CONTINUED)	138
REFERENCES (CONTINUED)	139
REFERENCES (CONTINUED)	140
REFERENCES (CONTINUED)	141
REFERENCES (CONTINUED)	142
REFERENCES (CONTINUED)	143
REFERENCES (CONTINUED)	144
REFERENCES (CONTINUED)	145
REFERENCES (CONTINUED)	146
REFERENCES (CONTINUED)	147
REFERENCES (CONTINUED)	148
REFERENCES (CONTINUED)	149
REFERENCES (CONTINUED)	150
REFERENCES (CONTINUED)	151
REFERENCES (CONTINUED)	152
REFERENCES (CONTINUED)	153